Journal Mobile Options
Table of Contents
Vol. 73, No. 1-2, 2007
Issue release date: March 2008
Section title: Clinical Study
Oncology 2007;73:21–25
(DOI:10.1159/000120028)

Low-Dose Chemotherapy in Combination with COX-2 Inhibitors and PPAR-Gamma Agonists in Recurrent High-Grade Gliomas – A Phase II Study

Hau P.f · Kunz-Schughart L.a · Bogdahn U.f · Baumgart U.f · Hirschmann B.f · Weimann E.b · Mühleisen H.c · Ruemmele P.d · Steinbrecher A.f · Reichle A.e
aOncoRay/ZIK Dresden, Dresden, bDepartment of Neurology, and cInstitute of Neuropathology, Institute of Pathology, Klinikum Ludwigsburg, Ludwigsburg, dPathology, and eDepartments of Oncology and fNeurology, University of Regensburg, Regensburg, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 8/16/2007
Accepted: 8/20/2007
Published online: 3/10/2008
Issue release date: March 2008

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 1

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Objectives: Combined treatment approaches targeting tumor as well as other cells contributing to tumor progression may control chemorefractory malignancies. Methods: A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma). Results: Fourteen patients were evaluable for response and toxicity. Major side effects were palmoplantar erythema, edema and motor neuropathy grade 3. Disease stabilizations lasting longer than 3 months were noted in 4 of 14 patients (29%). Clinical responses did not correspond to immunohistochemical staining for cyclooxygenase 2, peroxisome proliferator-activated receptor-γ and CD31. Discussion: The study demonstrates that this novel regimen is moderately active and well tolerated in patients with high-grade gliomas. As a comparably small proportion of patients responded, the regimen might only be suitable for a subset of highly selected patients.

© 2008 S. Karger AG, Basel


  

Author Contacts

Peter Hau, MD
Department of Neurology, University of Regensburg
District Medical Center, Universitätsstrasse 84
DE–93053 Regensburg (Germany)
Tel. +49 941 941 8083, Fax +49 941 941 3292, E-Mail peter.hau@medbo.de

  

Article Information

Received: August 16, 2007
Accepted after revision: August 20, 2007
Published online: March 10, 2008
Number of Print Pages : 5
Number of Figures : 1, Number of Tables : 1, Number of References : 19

  

Publication Details

Oncology (International Journal of Cancer Research and Treatment)

Vol. 73, No. 1-2, Year 2007 (Cover Date: March 2008)

Journal Editor: Markman M. (Houston, Tex.)
ISSN: 0030–2414 (Print), eISSN: 1423–0232 (Online)

For additional information: http://www.karger.com/OCL


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 8/16/2007
Accepted: 8/20/2007
Published online: 3/10/2008
Issue release date: March 2008

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 1

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.